Evolving strategies: future treatment of glioblastoma

Area of Science:

• Neuro-oncology
• Cancer biology
• Translational medicine

Background:

• Glioblastoma (GBM) remains a challenging brain tumor with limited effective treatments.
• Current therapies like alkylators and antiangiogenic agents offer some benefit but do not overcome resistance or significantly improve survival.
• VEGF-directed angiogenesis is crucial, but other proangiogenic pathways also drive GBM progression.

Purpose of the Study:

• To review current glioblastoma treatment limitations.
• To highlight the role of angiogenic signaling in GBM pathogenesis.
• To discuss preliminary results of novel antiangiogenic therapies for GBM.

Main Methods:

• Literature review of current GBM treatments.
• Analysis of the role of angiogenesis and other signaling pathways in GBM.
• Evaluation of emerging antiangiogenic and antiglioma treatment strategies.

Main Results:

• Existing treatments for glioblastoma have significant limitations.
• Multiple proangiogenic and glioma-promoting pathways contribute to tumor progression beyond VEGF.
• Novel therapies targeting multiple pathways, including angiogenesis, are under investigation.

Conclusions:

• Inhibiting multiple signaling pathways, particularly angiogenesis, offers a promising strategy for improving glioblastoma outcomes.
• Targeting combined pathways may overcome drug resistance and reduce toxicity.
• Multimodal therapeutic approaches hold potential for enhancing overall survival in GBM patients.